Published in AIDS Weekly, March 5th, 2007
This decision by the European Commission through a centralised procedure, signifies that the treatment is authorised for use in the European Union (EU), valid in all 27 EU member states.A conditional marketing authorisation was granted to PREZISTA(tm), taken in combination with ritonavir and other antiretroviral medicinal products, because of its benefits for HIV-1 infected patients, however,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.